[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Sandhu, Shahneen, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A., Williams, Scott G., Iravani, Amir, Martin, Andrew J., Davis, Ian D., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Sandhu, Shahneen, Redfern, AD, Macdonald, W, Guminski, A, Hsiao, E, Chua, W, Lin, P, Zhang, AY, Stockler, MR, Williams, SG, Martin, AJ, Iravani, Amir, Davis, ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group,, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D.

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

- Hofman, Michael S., Lawrentschuk, Nathan, Wong, Lih-Ming, Taubman, Kim, Ting Lee, Sze, Hsiao, Edward, Roach, Paul, Nottage, Michelle, Kirkwood, Ian, Hayne, Dickon, Link, Emma, Marusic, Petra, Francis, Roslyn J., Matera, A, Herschtal, A, Iravani, A, Hicks, RJ, Williams, S, Murphy, DG, Tang, Colin, Vela, Ian, Thomas, Paul, Rutherford, Natalie, Martin, Jarad M., Frydenberg, Mark, Shakher, Ramdave

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

- Siva, Shankar, Bressel, Mathias, Lin, Charles, Raman, Avi, Hardcastle, Nicholas, Hofman, Michael S., De Abreu Lourenco, Richard, Shaw, Mark, Mancuso, Pascal, Moon, Daniel, Wong, Lih-Ming, Lawrentschuk, Nathan, Sidhom, Mark, Wood, S, Brook, NR, Kron, T, Martin, Jarad, Pryor, D, FASTRACK II Investigator Group,, Sridharan, Swetha, Vanneste, Ben G. L., Davey, Ryan, Montgomery, Rebecca, Ruben, Jeremy, Foroudi, Farshad, Higgs, Braden